STAT2d
Biotech raising $35 million to take a second stab at cancer drug from Bert Vogelstein’s lab
A new biotech is raising money to develop a drug believed to be capable of starving cancer cells, based on research out of a ...
Axios on MSN7mon
An 83-year-old Duke professor's breakthrough research leads to new brain cancer drug
Driving the news: The drug, called Voranigo, is the result of collaborative research done by 83-year-old Duke ...
Hosted on MSN7mon
Novel Co-STAR cells show promise in targeting and eradicating cancer
Bert Vogelstein, M.D., co-senior investigator, Clayton Professor of Oncology, Howard Hughes Medical Institute investigator and co-director of the Ludwig Center "I was, honestly, incredibly ...
News Medical on MSN7mon
From discovery to approval: Vorasidenib approved by FDA for treatment of IDH-mutant gliomas
The gene was identified by Bert Vogelstein, M.D., and team at the Johns Hopkins Kimmel Cancer Center's Ludwig Center in 2008 ...
pharmaphorum11mon
Clasp emerges with $150m for safer T-cell engagers
The new company, based in Cambridge, Massachusetts and Rockville, Maryland, has been set up to commercialise TCE technology developed by Johns Hopkins University researchers Bert Vogelstein and ...
Nature14y
Oncology's energetic pipeline
In a plenary talk at this year's annual meeting of the American Association for Cancer Research in Washington, D.C., Bert Vogelstein predicted that future cancer cures will mostly come from ...
Benzinga.com2d
STAT+: Biotech raising $35 million to take a second stab at cancer drug from Bert Vogelstein's lab
A new biotech is raising money to develop a drug believed to be capable of starving cancer cells, based on research out of lauded cancer researcher Bert Vogelstein’s lab. The Boston-based ...